

Lupin, Phil Inc partner to deliver solutions for patients on Solosec®

02 February 2021 | News

Solosec® is the only single 2g oral dose therapy for the most common vaginal infection in the US among adult women



Lupin Pharmaceuticals, Inc, a global pharmaceutical company, has announced a partnership with Phil, Inc, which helps deliver cost-effective next-generation access solutions for patients who are prescribed Solosec® (secnidazole) 2g oral granules for the treatment of bacterial vaginosis (BV) in adult women.

Solosec® is the only single 2g oral dose therapy for the most common vaginal infection in the US among adult women. This treatment is designed to deliver a full course of therapy in just one packet.

"With the addition of Solosec® to the Phil platform, we are able to provide a convenient channel for physicians to prescribe Solosec® and enhance the patient experience," said Jon Stelzmler, President - Specialty, Lupin Pharmaceuticals, Inc.

"Phil offers a systemic solution for a systemic problem," Deepak Thomas, Founder, and CEO, Phil, Inc, said in a statement. "Because the underlying challenges in this space are experienced not just at the pharmacy but may extend to other stakeholders including prescribers and manufacturers, Phil aims to address these issues in their entirety."